Form 4: TScan Therapeutics Director Garry A. Nicholson Acquires Stock Options

Director Garry A. Nicholson acquired stock options in TScan Therapeutics, Inc. on June 12, 2024.

Summary

• Garry A. Nicholson, a director of TScan Therapeutics, Inc., acquired stock options on June 12, 2024.
• Nicholson acquired options to purchase 47,500 shares and 23,750 shares of voting common stock at an exercise price of $8.88.
• The first option for 47,500 shares vests fully on the earlier of June 12, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service.
• The second option for 23,750 shares vests with one-third of the shares on June 12, 2025, and the remaining balance vesting in 24 equal monthly installments, also contingent upon continued service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance, but rather aligns incentives.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, transact in their company's stock. These filings provide transparency into insider activity and can be used by investors to gauge sentiment.

Comparison to Industry Standards

• Stock option grants to directors are a common form of compensation in the biotechnology industry.
• The vesting schedules described are fairly standard, aligning with typical employment agreements and performance incentives.
• Comparable companies such as Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) also utilized stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grants align the director's interests with those of the shareholders, incentivizing them to work towards increasing the company's value.

Key Dates